Skip to main content

SEB Läkemedelsfond

SEB Läkemedelsfond is an equity fund managed by SEB in the Sektor – Helse category.

About this fund

Categorised as Sektor – Helse, SEB Läkemedelsfond is an equity fund from SEB.

The fund dates from 1988, giving it 38 years of history.

On return so far this year measured in NOK as of 13.11.2026, it places 11 of 18 funds in the group.

The reference index is MSCI World Health Care Net Return Index.

Manager
SEB
Category
Sektor – Helse
Region
Global
Sector
Diversified
Style
Large Blend
SFDR
Article 8
ISIN
SE0000984122
Inception
1988-04-11
Benchmark
MSCI World Health Care Net Return Index
AUM
18.0 bn SEK
Returns
YTD 5.1% · 1Y 8.9% · 3Y 10.1% · 5Y 8.5%

Portfolio managers

Formerly: SEB Concept Biotechnology Fund (Sep 2025 · merged into)
Actively managedEquityGlobal
YTD Return · NOK
+5,1 %from NAV
Calculated NOK return from SEK · (NOK Calculated)
Last NAV 152,17 EUR · 13 Nov 2026
Returns by period · NOK · net
ann. 3Y+
+5,1 %
YTD
+8,9 %
1y
+10,1 %
3y, annualised
+8,5 %
5y, annualised
+10,4 %
10y, annualised
Fund size
18,0 mrd. SEK
Total fund AUM
Management fee
1,50 %
Annual · 4 share classes
Ongoing charge
1,50 %
Annual
Annual cost on platforms
1,04 %–1,05 %
Class D · 2 platforms · net of platform rebate, incl. platform fee, excl. transaction costs
SFDR
Article 8
Sustainability
Launched
Apr 1988
ISIN SE0024788731
BenchmarkMSCI World Health Care · Net
About the fund
The fund

SEB Läkemedelsfond has a history going back to 1988. The management company is SEB Investment Management, legally SEB Funds AB since March 2025. It is wholly owned by the banking group SEB (Skandinaviska Enskilda Banken), headquartered in Stockholm. Day-to-day portfolio management is delegated to SEB Asset Management AB.

Investment philosophy

The fund invests across pharmaceuticals, biotechnology, medical technology and health care services. Sustainability analysis is integrated into investment decisions, and companies, business models and products judged to affect climate, society or stakeholders negatively are excluded.

The managers

The fund is managed by one person, Angelica Fatouros in Stockholm, who has managed it since February 2021, when she also became head of SEB's fundamental equity team. She holds a doctorate in pharmaceutical sciences and has long experience as an analyst in the pharmaceutical industry. She also manages SEB Bioteknikfond.

The portfolio

The active share is somewhat lower than that of comparable funds, so the portfolio sits closer to the sector index. The lasting top positions are large, established companies such as Eli Lilly, Merck, Johnson & Johnson and Thermo Fisher Scientific, across pharmaceuticals, medical devices and health services.

FundTelligence description · 18/10/2026
Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

Portfolio managers

AN
Portfolio Manager
On the fund since Feb 1, 2021

Position in the peer group

Sector Health Care Equities · 31 funds in the peer group. The number ranked and the date are stated per period. 12 of them converted to NOK.

7 of 18 funds ranked on a calculated return

#11/ 18Year to date
+5.13% NOK

as of 13 Nov 2026 · Converted from SEK to NOK

About the figures

13 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#13/ 221 year
+8.92% NOK

as of 13 Nov 2026 · Converted from SEK to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#4/ 223 years (ann.)
+10.14% NOK

as of 13 Nov 2026 · Converted from SEK to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#4/ 225 years (ann.)
+8.54% NOK

as of 13 Nov 2026 · Converted from SEK to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

Comparison basis

Year to date

Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

1 year

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

3 years (ann.)

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

5 years (ann.)

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.

Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.

About our data